Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 18Colonic Neoplasms 4Rectal Neoplasms 2Neoplasm Metastasis 2Stomach Neoplasms 1Solid Tumor Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Carcinoma 1Advanced/Metastatic Solid Tumors 1Advanced Gastric Cancer 1Adenocarcinoma 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × Trifluridine × 1 year × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡